Hosted on MSN16h
FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now?
We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...
Cantor Fitzgerald Weighs in on Zai Lab FY2025 Earnings
Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...
Zai Lab Gets FDA Orphan Drug Designation For ZL-1310 To Treat Small Cell Lung Cancer
Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...
Zai Lab’s Robust Product Growth and Portfolio Expansion Drive Buy Recommendation
Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...
Insider Monkey3d
Here’s Why Analysts Are Bullish on Zai Lab Limited (ZLAB)
We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against the other hot stocks.
High Growth Tech Stocks To Explore In January 2025
The United States market has shown robust performance with a 3.1% increase over the last week and a 24% rise over the past year, while earnings are projected to grow by 15% annually. In this favorable ...
Morningstar7d
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of ...
ETF Daily News4d
JPMorgan Chase & Co. Sells 106,397 Shares of Zai Lab Limited (NASDAQ:ZLAB)
JPMorgan Chase & Co. reduced its position in shares of Zai Lab Limited (NASDAQ:ZLAB – Free Report) by 43.5% during the 3rd quarter, according to its most recent Form 13F filing with the ...
Seeking Alpha29d
ZLAB Zai Lab Limited
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered ...
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...